Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression

Last updated: April 16, 2026
Sponsor: Assaf-Harofeh Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

hyperbaric oxygen therapy

Clinical Study ID

NCT07423273
0202-23
  • Ages 50-85
  • All Genders

Study Summary

The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age between 50 -85

  2. Suffered an ischemic stroke 6 months to 7 years prior to their inclusion

  3. Treated or being treated by antidepressants for at least 3 months

  4. Diagnosis of PSD based on HDRS-17 score of 17 and above.

  5. Stable psychological and pharmacological treatment for more than three months priorto inclusion.

  6. Subject willing and able to read, understand and sign an informed consent.

Exclusion

Exclusion Criteria:

  1. Inability to attend scheduled clinic visits and/or comply with the study protocol

  2. Diagnosis of a psychiatric disorder prior to the recent stroke including: majordepression, schizophrenia or bipolar disease.

  3. Diagnosis of aphasia or major cognitive decline

  4. History of Deep brain stimulation (DBS)

  5. History of traumatic brain injury, brain tumors, brain surgery, chronic subduralhaemorrhages, Epilepsy

  6. Active malignancy

  7. Substance use at baseline.

  8. History of other neurodegenerative diseases including Alzheimer's disease (AD),Parkinson's disease (PD), Lewy body dementia (LBD), Frontotemporal dementia (FTD),Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacobdisease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasaldegeneration (CBD), Wernicke Korsakoff syndrome

  9. Serious suicidal ideation

  10. Renal or liver insufficiency, electrolyte imbalances

  11. Chronic heart failure with ejection fraction of 30 or less

  12. HBOT for any reason prior to study enrolment

  13. Chest pathology incompatible with pressure changes (including active asthma or COPD)

  14. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologistvisits a year)

  15. An inability to perform an awake brain MRI

  16. No evidence of vascular related lesions in the brain MRI

  17. Active smoking

  18. Participation in another study

Study Design

Total Participants: 142
Treatment Group(s): 1
Primary Treatment: hyperbaric oxygen therapy
Phase:
Study Start date:
November 08, 2023
Estimated Completion Date:
December 01, 2030

Study Description

Post-stroke depression (PSD) is a prevalent mental health complication, affecting approximately 33% of stroke survivors. Its occurrence not only hinders rehabilitation and recovery from motor and cognitive deficits post-stroke but also escalates the risk of subsequent neurovascular events. Both biological and psychological factors are instrumental in the onset of PSD.

Ischemia plays a pivotal role in the development of long-term PSD due to its impact on specific brain regions, neurotransmitter systems, neural connectivity, inflammatory responses, and mitochondrial dysfunction.

brain ischemia can instigate a protracted cycle of inflammation, levels and functions of neurotransmitters, impaired mitochondrial function, that directly impinges on the brain's ability to undergo neuroplastic changes. This relationship underscores the importance of targeting the cure of brain ischemia in therapeutic strategies for PSD. Managing the brain ischemia could potentially salvage neuroplasticity and mitigate the mental and cognitive decline associated with PSD.

The new protocols of hyperbaric oxygen therapy (HBOT), using the hyperoxic-hypoxic paradox (HHP), is one of the first therapeutic intervention already in clinical use today for the specific goal of inducing regeneration of damaged brain tissue.

Cumulative data from recent years provide convincing evidence that HBOT can induce neuroplasticity leading to repair of chronically impaired brain functions and improved quality of life in post-stroke patients.

Both neurological and cognitive functions were improved even years after the stroke.

The observed restoration of neuronal activity in the metabolically dysfunctional stunned areas indicates that HBOT is a potent means of delivering sufficient oxygen needed for activation of neuroplasticty and restoration of impaired functions.

HBOT was found to be effective in small clinical trials for patients suffering from post-stroke depression. In a meta-analysis done by Liang et al. the efficacy and safety of HBOT for PSD was evaluated. A total of 27 RCTs involving 2250 participants were identified. Patients in HBOT group had a higher response rate than patients in control group (response rate: 69.4% vs 51.2%, odds ratio [OR] = 2.51, 95% confidence interval [CI] [1.83-3.43], P = 0.000). HBOT significantly reduced Hamilton Depression (HAMD).

The aim of the current study is to evaluate the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.

Connect with a study center

  • The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)

    Zrifin, 70300
    Israel

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.